Prevention of Menstruation with Leuprorelin (GnRH Agonist) in Women Undergoing Myelosuppressive Chemotherapy or Radiochemotherapy for Hematological Malignancies: a Pilot Study

References

• Ghalie R., Porter C., Radwanska E., Fitzsimmons W., Richman C., Kaiser H. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1993; 42: 350–353
   PubMed Web of Science ®Google Scholar
• Shaw R W. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol 1994; 101(suppl 11)15–18
   PubMedGoogle Scholar
• Friedman A J., Barbieri R L. Leuprolide acetate: applications in gynecology. Curr Probl Obstet Gynecol Fertil 1988; 11(6)205–236
   Google Scholar
• Dowsett M., Jacobs S., Aherne A., Smith I E. Clinical and endocrine effects of leuprorelin acetate in pre-and postmenopausal patients with advanced breast cancer. Clinical Therapeutics 1992; 14(suppl A)97–103
   PubMedGoogle Scholar
• George M., Lhommé C., Lefort J., Gras C., Comaru-Schally A M., Schally A. V. Long-term use of an LH-RH Agonist in the management of uterine leiomyomas: a study of 17 cases. Int J Fertil 1989; 34(1)19–24
   PubMedGoogle Scholar
• Savino L., Baldini B., Susini T. LH-RH analogs in gynecological oncology: a review. J Chemother 1992; 4: 312–320
   PubMed Web of Science ®Google Scholar
• Kienle E., Lübben G., Mulz D. Efficacy and safety of leuprorelin acetate depot for prostate cancer in a long-term follow-up study: preliminary results. Urol Int 1996; 56(suppl 1)21–28
   PubMedGoogle Scholar
• Mazzei T., Mini E., Rizzo M., Periti P. Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostate cancer patients. J Int Med Res 1990; 18(suppl 1)42–56
   PubMedGoogle Scholar
• Filicori M., Flamigni C. GnRH Agonists and antagonists. Current clinical status. Drugs 1988; 35: 63–82
   PubMed Web of Science ®Google Scholar
• Filicori M. Gonadotrophin-Releasing Hormone Agonist. A guide to use and selection. Drugs 1994; 48(1)41–59
   PubMed Web of Science ®Google Scholar
• Boucekkine C., Blumberg-Tick J., Roger M., Thomas F., Chaussain J. L. Le traitement des pubertés précoces centrales par la triptoréline à libération prolongée. Arch Pédriatr 1994; 1: 1127–1137
   PubMedGoogle Scholar
• Meldrum D R, Wisot A, Hamilton F, Gutlay A L, Huynh D, Kempton W. Timing of initiation and dose schedule of leuprolide influence the time course of ovarian suppression. Fertil Steril 1988; 50(3)400–402
   PubMed Web of Science ®Google Scholar
• Wade J C. Management of infection in patients with acute leukemia. Hematol. Oncol Clin North Am 1993; 7: 293–296
   PubMed Web of Science ®Google Scholar
• Lindgren A., Olisson R. Liver damage from low-dose oral contraceptives. J Intern Med 1993; 234: 287–291
   PubMed Web of Science ®Google Scholar
• Sica S., Salutari P., Di Mario A., Chiusolo P., Rutella S., Ortu La, Barbera E., Léone G., Scirpa P. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol 1996; 51: 248–249
   PubMed Web of Science ®Google Scholar
• Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 15: 4568–72
   Google Scholar
• Sullivan-Nelson M., Kuller J. A., Zacur H. A. Clinical use of oral contraceptives administered vaginally: a case report. Fert Steril 1989; 52: 864–865
   PubMed Web of Science ®Google Scholar
• Iwata M., Shirotake S., Hirahara F., Minaguchi H., Machida Y., Nagai T. Development and clinical evaluation of double-phased suppositories of progesterone with subtained release property. J Control Release 1994; 28(1–3)323–324
   Web of Science ®Google Scholar
• Sam A. P. Controlled release contraceptive devices: a status report. J Control Release 1992; 22: 35–46
   Web of Science ®Google Scholar
• Chiusolo P, Salutari P, Sica S, Scirpa P, Laurenti L, Piccirillo N, Leone G. Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant 1998; 21(8)821–823
   PubMed Web of Science ®Google Scholar
• Laufer M R, Townsend M L, Parsons K E, Brody K A, Diller L R, Emans S J, Guinan E C. J Reprod Med 1997; 42(9)537–541
   PubMed Web of Science ®Google Scholar
• Yagita M., Sugiyama H., Yasumoto H., Chinen Y, Takahashi T, Nakai Y., Imura H. Control of hypermenorrhea in female patients with severe thrombocytopenia with a special relevance to the efficacy of LH-RH analogue. J Clin Hematol 1983; 24: 1295–1302
   PubMedGoogle Scholar
• Uemura T., Namiki T., Kimura A., Yanagisawa T., Minaguchi H. Direct effects of gonatotropin-releasing hormone on the ovary in rats and humans. Horm Res 1994; 41(suppl 1)7–13
   PubMed Web of Science ®Google Scholar
• Jarrell J. F., Macmahon A., Barr R. D., Younglai E. V. The agonist (d-leu-6, des-gly-10)-LHRH-ethylamide does not protect the fecundity of rats exposed to high dose unilateral ovarian irradiation. Reprod Toxicol 1991; 5: 385–388
   PubMed Web of Science ®Google Scholar
• Ataya F., Pydyn E., Ramahi-Ataya A., Orion C. G. Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: preliminary observations. J Clin Endocrinol 1995; 80(3)790–795
   Web of Science ®Google Scholar
• Waxman J H, Ahmed R, Smith D, Wrigley P F, Gregory W, Shalet S, Crowther D, Rees L H, Besser G M, Malpas J S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19(2)159–162
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11(8)1620–1626
   PubMed Web of Science ®Google Scholar
• Surrey E. S., Judd H. L. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992; 75: 558–563
   PubMed Web of Science ®Google Scholar
• Judd H. L. Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy. Am J Obstet Gynecol 1992; 166: 752–756
   PubMed Web of Science ®Google Scholar
• Uemura T., Mohri J., Osada H., Suzuki N., Katagiri N., Minaguchi H. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fert Steril 1994; 62(2)246–250
   PubMed Web of Science ®Google Scholar
• Scialli A. R., Jestila K. J., Simon J. A. Leuprolide acetate and bone mineral density measured by quantitative digitized radiography. Fert Steril 1993; 59(3)674–676
   PubMed Web of Science ®Google Scholar
• Surrey E. S. Steroidal and nonsteroidal “add-back” therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient. Fert Steril 1995; 64(4)673–685
   PubMed Web of Science ®Google Scholar
• Riis B. J., Christiansen C., Johansen J. S., Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?. J Clin Endocrinol Metab 1990; 70: 920–924
   PubMed Web of Science ®Google Scholar
• Altes A., Brunet S., Calaf J., Capdevila E., Nomdedeu J., Sureda A. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1994; 46(1)60–61
   PubMed Web of Science ®Google Scholar
• Jones N S, Quraishi S, Mason J D. The nasal delivery of systemic drugs. Int J Clin Pract 1997; 51(5)308–311
   PubMed Web of Science ®Google Scholar